Gene Therapy in Fanconi Anemia

In this virtual panel hosted by the Fanconi Anemia Research Fund (FARF), our Chief Medical Officer, Dr. Jonathan Schwartz, speaks about Rocket’s gene therapy program for Fanconi Anemia (FA) and gives an update on our FA gene therapy trials taking place in Stanford and Spain. Dr. Juan Bueren, Director of Hematopoietic Innovative Therapies Division at CIEMAT in Madrid, Spain and Dr. Agnieszka Czechowicz, Assistant Professor of Pediatric System Cell Transplant at Stanford Medicine also provide more detail about Rocket’s clinical trials in Spain and Stanford, respectively.

Fanconi Anemia Research Fund:    / @fanconicancerfoundation